Marc Hoffman, MD
In this episode, we’re joined by Dr. Marc Hoffmann from The University of Kansas Cancer Center, to explore chronic lymphocytic leukemia (CLL)—what it is, how it’s treated today, and where research is headed. Dr. Hoffmann shares insights on treatment goals, side effect management, and the importance of shared decision making. We also touch on emerging therapies—including CAR T-cell therapy and bispecifics—and end with a message of hope for those navigating life after a CLL diagnosis.
Podcast: Play in new window | Download
Subscribe: Spotify | Pandora | Blubrry | Podchaser | More
CLICK HERE to participate in our episode survey.Mentioned on this episode:
- Chronic Lymphocytic Leukemia
- Shared Decision-Making Chronic Leukemias Interactive Program
- CAR T-cell therapy
- Allogeneic stem cell transplantation
- LLS Clinical Trial Support Center
- Financial support
- How Far Have We Come: Mantle Cell Lymphoma – Dr. Jacob Soumerai
Additional LLS Support Resources:
- Free Nutrition Consultations
- Information Specialists
- Free telephone/web patient programs
- Free booklets
- Young Adult Resources
- Support groups
- Caregiver support
- Caregiver Workbook
- Survivorship Workbook
- Advocacy and Public Policy
- LLS Community
- Mental Health Resources
Supported by AbbVie Inc., Medicines and Genentech, A Member of the Roche Group.
This was a great episode for me to hear! The most important takeaways for me: after diagnosis is challenging and confusing (especially for those of us who want to plan ahead); most CLL patients will never need some of the amazing new therapies we hear about; and make friends with your diagnosis/disease.
Also, informed opinions by doctors about Medicare or Medicare Advantage and treatment expense are helpful for those of us new to Medicare. We need to have honest discussions about treatment expense. This is a huge area of concern for me. Valid information helps when it is time to make those healthcare plan choices. It is a huge source of anxiety and stress.